Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - purified tetanus toxoid; purified diphtheria toxoid ph. eur.; adsorbed purified pertussis toxoid; adsorbed purified filamentous haemagglutinin; inactivated poliomyelitis virus ph. eur; inactivated type 1 poliovirus; inactivated type 2 poliovirus; inactivated type 3 poliovirus - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - bacterial and viral vaccines, combined; diphtheria-pertussis-poliomyelitis-tetanus

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines inc. - diphtheria, tetanus and pertussis (acellular component), hepatitis b (rdna), poliomyelitis (inactivated) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) (preservative-free)

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and haemophilus influenzae type b conjugate vaccine, adsorbed - suspension for injection (deep i.m.), 2pe free - 0.5 ml

Philippines - English - FDA (Food And Drug Administration)

glovax biotech corp.; distributor: glovax biotech corp. - adsorbed diphtheria-tetanus-pertussis-hepatitis b (rdna) and haemophilus influenzae type b conjugate vaccine - solution for im injection - [see reverse]

Philippines - English - FDA (Food And Drug Administration)

glovax biotech corp.; distributor: glovax biotech corp. - adsorbed diphtheria-tetanus-pertussis-hepatitis b (rdna) and haemophilus influenzae type b conjugate vaccine - solution for im injection - 0.5ml

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: ip biotech, inc.; distributor: ip biotech, inc. - diphtheria, tetanus, pertussis (whole cell), hepatitis b (rdna) and haemophilus influenzae type b conjugate vaccine (adsorbed) - solution for injection (i.m) - each dose (0.5 ml) contains: diphtheria toxoid ................... 25 lf ( > 30 iu) tetanus toxoid ...................... 5.5 lf (> 60 iu) b. pertussis (whole cell) ........... 16 iou ( >4 iu) hepatitis b (rdna) ................ 12.5 ug purified capsular polysaccharide (prp) of hib covalently linked to 20 to 36.7 ug of tetanus toxoid .... ............... 11 ug alt+t (as alpo4) ........ ............. <1.25 mg thiomersal ............ ........... 0.01% w/v

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: ip biotech, inc.; distributor: ip biotech, inc. - diphtheria, tetanus, pertussis (whole cell), hepatitis b (rdna) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) - each dose (0.5 ml) contains: diphtheria toxoid 25 lf 30 iu) tetanus toxoid....................... 5.5 lf 60 iu) b. pertussis (whole cell ............ 16 iou ( 4 iu) hepatitis b (rdna)................12.5 ug purified capsular polysaccharide (prp) of hib covalently linked to 20 to 36.7 ug of tetanus toxoid ..................11 ug alt++ (as alpo4)..................... 51.25 mg thiomersal .......... 0.01% w/v

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (20-40mcg of tetanus toxoid per dose);   - powder for injection with diluent - 0.5 ml - excipient: sodium chloride water for injection active: haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (20-40mcg of tetanus toxoid per dose)   excipient: lactose water for injection - hiberix is indicated for active immunisation of all infants from the age of 6 weeks against disease caused by hib. hiberix does not protect against diseases due to other types of h. influenzae, nor against meningitis caused by other organisms.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 30 [iu] (> or =); pertactin 8ug; pertussis filamentous haemagglutinin 25ug; pertussis toxoid, adsorbed 25ug; tetanus toxoid 40 [iu] (> or =); haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (as prp (target fill 10mcg + 2.5mcg overage)); diphtheria toxoid, adsorbed 30 [iu] (> or =); pertactin 8ug; pertussis filamentous haemagglutinin 25ug; pertussis toxoid, adsorbed 25ug; tetanus toxoid 40 [iu] (> or =) - suspension for injection - active: diphtheria toxoid, adsorbed 30 [iu] (> or =) pertactin 8ug pertussis filamentous haemagglutinin 25ug pertussis toxoid, adsorbed 25ug tetanus toxoid 40 [iu] (> or =) excipient: aluminium hydroxide sodium chloride water for injection active: haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (as prp (target fill 10mcg + 2.5mcg overage)) excipient: lactose monohydrate sodium chloride water active: diphtheria toxoid, adsorbed 30 [iu] (> or =) pertactin 8ug pertussis filamentous haemagglutinin 25ug pertussis toxoid, adsorbed 25ug tetanus toxoid 40 [iu] (> or =) excipient: aluminium hydroxide phenoxyethanol sodium chloride water for injection - infanrixtm-hib is indicated for active immunisation against diphtheria, tetanus, pertussis (dtp) and haemophilus influenzae type b (hib) infection in all children from 15 months of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth (nz) ltd - diphtheria toxoid, adsorbed 25 lf u/ml; haemophilus influenzae type b oligosaccharide vaccine-crm 197 conjugate 50 µg/ml; haemophilus influenzae type b vaccine 20 µg/ml; pertussis vaccine, adsorbed 32 iou; tetanus toxoid, adsorbed 10 lf u/ml - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 25 lf u/ml haemophilus influenzae type b oligosaccharide vaccine-crm 197 conjugate 50 µg/ml haemophilus influenzae type b vaccine 20 µg/ml pertussis vaccine, adsorbed 32 iou tetanus toxoid, adsorbed 10 lf u/ml excipient: aluminium sodium chloride thiomersal water for injection